0000000000268943

AUTHOR

Lip G. Y. H.

showing 5 related works from this author

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation

2006

Aims To describe guideline adherence and application of different stroke risk stratification schemes regarding antithrombotic therapy in real-life atrial fibrillation (AF) patients and to assess which factors influence antithrombotic management decisions. Methods and results The Euro Heart Survey enrolled 5333 AF patients in 35 countries, in 2003 and 2004. Prescription of antithrombotic drugs, especially oral anticoagulation (OAC), was hardly tailored to the patient's stroke risk profile as indicated by the joint guidelines of the American College of Cardiology, American Heart Association, and the European Society of Cardiology, ACCP guidelines, or CHADS2 and Framingham risk scores. In mult…

AdultMalemedicine.medical_specialtyOral anticoagulationGuidelineRisk AssessmentElectrocardiographyFibrinolytic AgentsRisk FactorsDrug CombinationAntithromboticmedicineHumansOutpatient clinicRisk factorMultivariate AnalysiStrokeRisk stratificationAgedAntithrombotic therapyFibrinolytic AgentFramingham Risk Scorebusiness.industryRisk FactorAtrial fibrillationMiddle Agedmedicine.diseaseAtrial fibrillationStrokeDrug CombinationsMultivariate AnalysisPractice Guidelines as TopicEmergency medicinePhysical therapyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessCardioversionsRisk assessmentHumanEuropean Heart Journal
researchProduct

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Surve…

2018

Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF,…

MalePROGNOSISHypertension Left Ventricular Hypertrophy Atrial FibrillationRHYTHM-CONTROL THERAPYBlood PressureComorbidity030204 cardiovascular system & hematologyLeft ventricular hypertrophy0302 clinical medicineHeart RateRisk FactorsAtrial FibrillationRegistries030212 general & internal medicineStrokeRISKmedicine.diagnostic_testIncidencePULSE PRESSUREWOMENAtrial fibrillationMiddle AgedPulse pressureEuropeSurvival RateEchocardiographyPopulation SurveillanceHypertensionDisease ProgressionCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicineSTROKEmedicine.medical_specialtyCANADIAN REGISTRY03 medical and health sciencesAge DistributionInternal medicinemedicineHumansCOHORTcardiovascular diseasesSex DistributionRisk factorRetrospective Studiesbusiness.industryOdds ratiomedicine.diseaseComorbidityATHEROSCLEROSISElectrocardiography AmbulatorybusinessFOLLOW-UPElectrocardiographyFollow-Up Studies
researchProduct

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey

2010

Objective: Despite extensive use of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and the increased bleeding risk associated with such OAC use, no handy quantification tool for assessing this risk exists. We aimed to develop a practical risk score to estimate the 1-year risk for major bleeding (intracranial, hospitalization, hemoglobin decrease >2 g/L, and/or transfusion) in a cohort of real-world patients with AF. Methods: Based on 3,978 patients in the Euro Heart Survey on AF with complete follow-up, all univariate bleeding risk factors in this cohort were used in a multivariate analysis along with historical bleeding risk factors. A new bleeding risk score terme…

MaleFibrinolytic AgentPrognosiIncidencePlatelet Aggregation InhibitorRisk FactorHemorrhageRisk AssessmentFollow-Up StudieEuropeStrokeProspective StudiePopulation SurveillanceAtrial FibrillationFemaleAgedHuman
researchProduct

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The …

2010

Background: Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts. Thus, many potential risk factors have not been included. Methods: We refined the 2006 Birmingham/National Institute for Health and Clinical Excellence (NICE) stroke risk stratification schema into a risk factor-based approach by reclassifying and/or incorporating additional new risk factors where relevant. This schema was then compared with existing stroke risk stratification schema in a real-world cohort of patients with AF (n = 1,084) from the Euro Heart Survey for AF. R…

MalePrognosiIncidenceRisk FactorReproducibility of ResultRisk AssessmentFollow-Up StudieEuropeStrokeRetrospective StudiePopulation SurveillanceThromboembolismAtrial FibrillationFemaleAgedHuman
researchProduct

Atrial fibrillation management: A prospective survey in ESC Member Countries - The Euro Heart Survey on atrial fibrillation

2005

Aims To describe atrial fibrillation (AF) management in member countries of the European Society of Cardiology (ESC) and to verify cardiology practices against guidelines. Methods and results Among 182 hospitals in 35 countries, 5333 ambulant and hospitalized AF patients were enrolled, in 2003 and 2004. AF was primary or secondary diagnosis, and was confirmed on ECG in the preceding 12 months. Clinical type of AF was reported to be first detected in 978, paroxysmal in 1517, persistent in 1167, and permanent in 1547 patients. Concomitant diseases were present in 90% of all patients, causing risk factors for stroke to be also highly prevalent (86%). As many as 69% of patients were symptomatic…

AdultHeart FailureMaleRate controlRisk FactorCardiologyCoronary Artery DiseaseGuidelineMiddle AgedAtrial fibrillationEuropeStrokeAnticoagulationProspective StudieAnti-Arrhythmia AgentEchocardiographyHypertensionPractice Guidelines as TopicRhythm controlFemaleSocieties MedicalAgedHuman
researchProduct